The stock of Nektar Therapeutics (NKTR, Financial) experienced a notable uptick, climbing 5.04% to $1.25 per share, with a trading volume of 291,971 shares and a turnover rate of 0.16%. The stock's volatility was marked at 2.69%.
Recent financial reports reveal that Nektar posted a revenue of $23.49 million, a net loss of $52.36 million, and an earnings per share of -$0.25. The company's gross profit was reported at $13.75 million, resulting in a price-to-earnings ratio of -1.38.
Regarding analyst ratings, among six participating institutions, 17% recommended buying the stock, 67% advised holding, and 16% suggested selling.
In the broader biotechnology sector, which rose by 0.75%, several related stocks also saw significant activity. Companies like Revolution Medicines, Athira Pharma, and Eupraxia Pharmaceuticals experienced notable increases, while others such as Theriva Biologics, Ensysce Biosciences, and Gri Bio were particularly active. High volatility was observed in stocks like Klotho Neurosciences, Tc Biopharm, and Immatics N.V., with respective fluctuations of 122.67%, 96.49%, and 60.77%.
Nektar Therapeutics is a biopharmaceutical company focused on oncology, immunology, and virology. It has a fully-owned R&D pipeline and several approved collaborative drugs. In oncology, Nektar aims to research immuno-oncology candidates to activate the body's natural anti-tumor mechanisms. The company addresses immune system imbalances in immunology to restore self-tolerance and achieve immune homeostasis. In virology, it believes selective immune modulators can tackle viral infections. Nektar's revenue is generated from the U.S. and globally.
